CALIX, INC

During the three months ended March 29, 2025, no director or officer of the Company (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended)adopted, terminated or modified a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as follows:

On February 7, 2025, Cory Sindelar, Chief Financial Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Sindelar 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Sindelar 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 130,000 shares of Common Stock, at specific market prices, commencing on May 9, 2025, and continuing until all such options are exercised and the underlying shares are sold, or June 30, 2026, whichever comes first.

On February 28, 2025, Michael Weening, Director, President and Chief Executive Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Weening 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Weening 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 974,000 shares of Common Stock, at specific market prices, commencing on May 30, 2025, and continuing until all such options are exercised and the underlying shares are sold, or February 28, 2026, whichever comes first.